TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15685822

Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide followed by paclitaxel alone or combined with gemcitabine for four cycles each
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Paclitaxel alone or combined with gemcitabine
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Epirubicin/cyclophosphamide
Number of subjects: 3000
Study: 11182006

Group type: EXPERIMENTAL
Intervention: Rifampicin and Ethambutol (RE)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Rifampicin, Ethambutol, and Isoniazid (REH)
Number of subjects: 223
Study: 9692413

Group type: EXPERIMENTAL
Intervention: Controlled-release low dose aspirin (75 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conventional formulation aspirin (75 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7837399

Group type: EXPERIMENTAL
Intervention: High dose epidural fentanyl (HEF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Epidural mepivacaine (M)
Number of subjects: 25
Study: 2898502

Group type: EXPERIMENTAL
Intervention: Preoperative antiseptic care
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24 h cephalosporin prophylaxis
Number of subjects: 0
Study: 30912721

Group type: EXPERIMENTAL
Intervention: Intraoperative MRI
Number of subjects: 200000

Group type: COMPARATOR
Intervention: Control (without intraoperative MRI)
Number of subjects: 200000
Study: 28923623

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 40

Group type: COMPARATOR
Intervention: MMF (50% reduction)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Everolimus (conversion from MMF)
Number of subjects: 40
Study: 25973704

Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients
Number of subjects: 1177
Study: 23799913

Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 20% responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 20% nonresponders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21745116

Group type: EXPERIMENTAL
Intervention: MPCNL irrigation and clearance system
Number of subjects: 60

Group type: COMPARATOR
Intervention: EMS ultrasound/ballistic trajectory lithotripsy and clearance system
Number of subjects: 60
Study: 19901118

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 16309749

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with myringotomy and ventilation tube insertion (study group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Adenoidectomy with myringotomy (control group)
Number of subjects: 45
Study: 15270993

Group type: EXPERIMENTAL
Intervention: Racial and opinion minority members in small-group discussions
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Groups with racial- and opinion-minority members
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Participants with racially diverse friends and classmates
Number of subjects: 357
Study: 10912607

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive physical therapy
Number of subjects: 0
Study: 9084455

Group type: EXPERIMENTAL
Intervention: 10 mg/m2 dose of pegylated-liposomal doxorubicin for the first cycle, followed by 20 mg/m2 every 3 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 20 mg/m2 dose of pegylated-liposomal doxorubicin every 3 weeks
Number of subjects: 43
Study: 1532127

Group type: EXPERIMENTAL
Intervention: Highly concentrated ethyl esters of n-3 fatty acids (85% eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Corn oil (56% linoleic and 26% oleic acid)
Number of subjects: 23
Study: 4096777

Group type: EXPERIMENTAL
Intervention: Derotation brace
Number of subjects: 42

Group type: COMPARATOR
Intervention: No brace (control condition)
Number of subjects: 42
Study: 31543516

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium intake with Ca:Mg ratio between 1.7 and 2.5
Number of subjects: 0
Study: 30541254

Group type: EXPERIMENTAL
Intervention: Perindopril arginine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 40
Study: 26355169

Group type: EXPERIMENTAL
Intervention: Calcium‐incorporated implants (Xpeed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control resorbable blasted media (RBM) implants
Number of subjects: 60
Study: 23342969

Group type: EXPERIMENTAL
Intervention: Brassica rapa ethanol extract (BREE) 2 g/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (starch, 2 g/day)
Number of subjects: 58
Study: 22555246

Group type: EXPERIMENTAL
Intervention: Basic web-based weight-loss program
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Enhanced web-based weight-loss program
Number of subjects: 309

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 309
Study: 18977811

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral tizanidine (TZD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17478080

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 17
Study: 14969403

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1593

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1593
Study: 12370455

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tricyclic Antidepressants (TCA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 9650873

Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush (group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Manual toothbrush (group A)
Number of subjects: 62
Study: 10187881

Group type: EXPERIMENTAL
Intervention: Glucose potassium insulin (GKI) infusion at 100 mL/h consisting of 16 U human soluble insulin and 20 mmol potassium chloride in 500 mL 10% glucose
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 53
Study: 1854670

Group type: EXPERIMENTAL
Intervention: 100 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 900 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 24
Study: 6843194

Group type: EXPERIMENTAL
Intervention: MIM system
Number of subjects: 519

Group type: COMPARATOR
Intervention: Control
Number of subjects: 519
Study: 30855640

Group type: EXPERIMENTAL
Intervention: Betamethasone treatment
Number of subjects: 2821

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2821
Study: 29390054

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan hydrochloride and docetaxel
Number of subjects: 0
Study: 27349715

Group type: EXPERIMENTAL
Intervention: Local liposomal bupivacaine (LB) - 20 mL of bupivacaine/10 mL of saline solution
Number of subjects: 82

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (FNB)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Local liposomal bupivacaine (LB)
Number of subjects: 82
Study: 24929613

Group type: EXPERIMENTAL
Intervention: Heavy hip extension strength training (HET)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Heavy hip flexion strength training (HFT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 27
Study: 22190678

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 20459820

Group type: EXPERIMENTAL
Intervention: Six-monthly monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-monthly monitoring (Control)
Number of subjects: 0
Study: 18250253

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pretreatment with lamotrigine (300 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (lamotrigine)
Number of subjects: 33
Study: 15914532

Group type: EXPERIMENTAL
Intervention: 1 pmol/kg.min ghrelin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 5 pmol/kg.min ghrelin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 12022597

Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 48

Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 48
Study: 9875583

Group type: EXPERIMENTAL
Intervention: Isoniazid (H) 6 months, twice a week
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Rifampicin (R) plus Pyrazinamide (Z) 3 months, twice a week
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1053
Study: 8275793

Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation (NPV) applied by an airtight jacket (pneumosuit), 5 hours a day, 5 consecutive days a week for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (in-hospital pulmonary rehabilitation program for 4 weeks)
Number of subjects: 13
Study: 2743201

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrocarbonate
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride plus 0.5% bupivacaine hydrochloride
Number of subjects: 100
Study: 1095306

Group type: EXPERIMENTAL
Intervention: 750 mg diftalone daily for 2 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: 100 mg indomethacin daily for 2 weeks
Number of subjects: 70
Study: 31888740

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA‐enriched medium/long‐chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide® 20%, B. Braun Melsungen AG)
Number of subjects: 160
Study: 29100193

Group type: EXPERIMENTAL
Intervention: Eribulin plus gemcitabine (EG)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (PG)
Number of subjects: 118
Study: 25608246

Group type: EXPERIMENTAL
Intervention: X-Stop
Number of subjects: 96

Group type: COMPARATOR
Intervention: Minimally invasive decompression
Number of subjects: 96
Study: 23568228

Group type: EXPERIMENTAL
Intervention: MI-CBT counseling with mDOT for 24 weeks
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MI-CBT counseling alone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 204
Study: 20497239

Group type: EXPERIMENTAL
Intervention: DHEA 25 mg/day p.o. for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no hormone replacement)
Number of subjects: 27
Study: 18257399

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy and radiation therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sequential chemotherapy and surgery
Number of subjects: 70
Study: 17233363

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% hyperbaric tetracaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study: 12502993

Group type: EXPERIMENTAL
Intervention: DuraPrep
Number of subjects: 60

Group type: COMPARATOR
Intervention: povidone iodine (PI)
Number of subjects: 60
Study: 10714612

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac‐Na effervescent (fast-release NSAID)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac‐Na effervescent (fast-release NSAID)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50 mg diclofenac tablets (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8854192

Group type: EXPERIMENTAL
Intervention: Protocol 5: biphasic injection of 100 mL of iohexol 300 (g/100 mL) at a flow rate of 1.5 mL/second followed by 25 mL at 2 mL/second; total iodine load = 37.5 g, with a scan delay of 70 seconds
Number of subjects: 121

Group type: COMPARATOR
Intervention: Protocol 1-4 (not specified in detail)
Number of subjects: 121
Study: 1339054

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 24
Study: 4003916

Group type: EXPERIMENTAL
Intervention: 0.3 ppm ozone exposure
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 13
Study: 30577864

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF) treatment (5 μg/kg/day for 5 days followed by every 3 days) in patients with partial response (PR) to corticosteroids.
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF) treatment in patients with null response (NR) to corticosteroids.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Prednisolone (40 mg/day for 1 week) followed by 28 days of treatment and tapering for an additional 2 weeks in patients with partial response (PR).
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo in patients with partial response (PR) to corticosteroids.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo in patients with null response (NR) to corticosteroids.
Number of subjects: 268
Study: 26676273

Group type: EXPERIMENTAL
Intervention: Pink-veneered zirconia abutments (CR-P, SR-P)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonveneered zirconia abutments (CR-W, SR-W)
Number of subjects: 44
Study: 25294223

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus brevis KB290 (about 6 billion colony-forming units)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: No treatment (Group A)
Number of subjects: 1089
Study: 23237122

Group type: EXPERIMENTAL
Intervention: Repeat Pap smear after a normal Pap smear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat Pap smear after an inadequate smear result
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-grade squamous intra-epithelial lesions (HSILs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors associated with abnormal cytology
Number of subjects: 0
Study: 20307378

Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 18301879

Group type: EXPERIMENTAL
Intervention: Pre-operative heparin infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16042029

Group type: EXPERIMENTAL
Intervention: Fluent aphasics (FA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alzheimer's type dementia (DAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAT patients with lexical‐semantic deficit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAT patients with conceptual deficit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 12079501

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (administered by intravenous infusion every two weeks for 6 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 10418756

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g once daily (CTX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy (STD)
Number of subjects: 100
Study: 7740639

Group type: EXPERIMENTAL
Intervention: Citalopram (10-40 mg/day) for three and six weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Citalopram (10-40 mg/day)
Number of subjects: 66
Study: 2040715

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 55

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 6799913

Group type: EXPERIMENTAL
Intervention: Nose obstructed
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nose open
Number of subjects: 8
Study: 31207693

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (routine general anesthesia)
Number of subjects: 150
Study: 28302703

Group type: EXPERIMENTAL
Intervention: Multi-element psychosocial intervention
Number of subjects: 444

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 444
Study: 27697302

Group type: EXPERIMENTAL
Intervention: EP-1300 polyepitope DNA vaccine administered via electroporation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 25071414

Group type: EXPERIMENTAL
Intervention: Structured oral information in addition to standard care, covering procedural, sensory, and coping information, and individualized fears and questions; administered in a single episode lasting 10-15 minutes.
Number of subjects: 211

Group type: COMPARATOR
Intervention: Non-specific episodic conversation of similar length in addition to standard care; administered in a single episode lasting 10-15 minutes.
Number of subjects: 211
Study: 21355727

Group type: EXPERIMENTAL
Intervention: Calsulin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19969180

Group type: EXPERIMENTAL
Intervention: H-reflex gain measurement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Presynaptic inhibition measurement
Number of subjects: 30
Study: 17370153

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (adaptive servoventilation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal drug therapy for heart failure
Number of subjects: 0
Study: 15730636

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg, twice daily for 5 days
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Control group (symptom relief medicine)
Number of subjects: 1176
Study: 11777221

Group type: EXPERIMENTAL
Intervention: Clariscan 0.75 mg Fe/kg body weight
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clariscan 2 mg Fe/kg body weight
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clariscan 5 mg Fe/kg body weight
Number of subjects: 6
Study: 9133758

Group type: EXPERIMENTAL
Intervention: Sertraline (n = 56)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Imipramine (n = 52)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 168
Study: 8201224

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 750 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3296605

Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 29868853

Group type: EXPERIMENTAL
Intervention: Verinurad combined with febuxostat (2.5-10 mg with febuxostat 10, 20, 40 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Verinurad alone (2.5-15 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Febuxostat alone (10, 20, 40 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Benzbromarone alone (50 mg)
Number of subjects: 72
Study: 26882370

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) formula
Number of subjects: 141

Group type: COMPARATOR
Intervention: Lower protein (LP) formula
Number of subjects: 141

Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 141
Study: 25338798

Group type: EXPERIMENTAL
Intervention: Periodontal-pulp combined therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Periodontal therapy (Control)
Number of subjects: 52
Study: 23744101

Group type: EXPERIMENTAL
Intervention: ICD implantation without intraoperative testing
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Shock path reversal
Number of subjects: 609
Study: 19468759

Group type: EXPERIMENTAL
Intervention: Discharge-planning program, discharge teaching, home visits, and telephone consultation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 18460487

Group type: EXPERIMENTAL
Intervention: Sous vide cooked salmon fish
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bean meal (rich in phytate)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fish and bean meal
Number of subjects: 21
Study: 17145226

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 mug/kg/min for 24 hours)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12691128

Group type: EXPERIMENTAL
Intervention: Quantitative gated myocardial SPECT (QGS) with 99mTc-tetrofosmin
Number of subjects: 179
Study: 10972599

Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epinephrine (0.03 microg/kg/min)
Number of subjects: 20
Study: 8873202

Group type: EXPERIMENTAL
Intervention: Two modes of presentation (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two different presentation rates (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two significantly different levels of adult intelligence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Compressed speech technology (not specified)
Number of subjects: 0
Study: 1305670

Group type: EXPERIMENTAL
Intervention: Zaditen (ketotifen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3893329

Group type: EXPERIMENTAL
Intervention: Current formula milk
Number of subjects: 10

Group type: COMPARATOR
Intervention: Earlier type with higher protein and mineral content
Number of subjects: 10
Study: 31092727

Group type: EXPERIMENTAL
Intervention: Transitional B cells in healthy donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mature B cells in healthy donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transitional to mature B cells in SLE patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mature B cells from healthy donors
Number of subjects: 0